Van Metre T E, Adkinson N F, Amodio F J, Kagey-Sobotka A, Lichtenstein L M, Mardiney M R, Norman P S, Rosenberg G L
J Allergy Clin Immunol. 1982 Feb;69(2):181-93. doi: 10.1016/0091-6749(82)90098-7.
In 44 patients highly sensitive to ragweed, we compared weekly injections of single doses of ragweed extract (RW-Wk, 15 patients) with clustered doses of ragweed extract at 3-wk intervals (RW-Cl, 18 patients) for effects on ragweed hay fever symptom-medication scores and immunologic variates. Patients were matched and randomly assigned to treatment groups. Ragweed doses were advanced to the highest tolerated dose. Doses and number of visits were lower in the RW-Cl group than in the RW-Wk group. Despite lower doses, systemic reactions were not reduced and antiragweed IgE levels increased significantly more in the RW-Cl group than those in the RW-Wk group. Both the RW-Cl and RW-Wk groups had significant increases in antiragweed IgG levels, decreases in seasonal rise in antiragweed IgE levels, and lower symptom-medication scores (p less than 0.01) in comparison with the placebo group. We conclude that the RW-Cl regimen offered no important advantage over RW-Wk. Seventeen patients had previously received Rinkel-method immunotherapy with 0.5 ml of end-point dilution of ragweed extract for 1 to 2 yr without significant clinical improvement or immunologic changes. After adequate treatment with either RW-Wk or RW-Cl, these patients had significantly lower symptom-medication scores than those of the placebo groups and immunologic changes similar to those of the entire active-treatment group. Therefore, treatment failures on Rinkel immunotherapy respond well to adequate dose immunotherapy by either schedule.
在44例对豚草高度敏感的患者中,我们比较了每周注射单剂量豚草提取物(RW-Wk组,15例患者)与每3周注射一次聚集剂量豚草提取物(RW-Cl组,18例患者)对豚草花粉症症状-用药评分和免疫学变量的影响。患者经匹配后随机分配至治疗组。豚草剂量逐渐增加至最高耐受剂量。RW-Cl组的剂量和就诊次数均低于RW-Wk组。尽管剂量较低,但RW-Cl组的全身反应并未减少,且抗豚草IgE水平的升高显著高于RW-Wk组。与安慰剂组相比,RW-Cl组和RW-Wk组的抗豚草IgG水平均显著升高,抗豚草IgE水平的季节性升高均降低,症状-用药评分均降低(p<0.01)。我们得出结论,RW-Cl方案相对于RW-Wk方案没有重要优势。17例患者此前接受了Rinkel法免疫治疗,用0.5 ml豚草提取物终点稀释液治疗1至2年,临床症状无明显改善,免疫学指标也无变化。在用RW-Wk或RW-Cl进行充分治疗后,这些患者的症状-用药评分显著低于安慰剂组,免疫学变化与整个积极治疗组相似。因此,Rinkel免疫治疗失败的患者对两种方案的充分剂量免疫治疗反应良好。